Conditions: Kidney Transplantation
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 3
Healthy volunteers: yes

Brief summary:
The primary objective of this study is to demonstrate that administration of belatacept in maintenance kidney transplant recipients may cause a reduction in Donor Specific HLA Antibody (DSA).

Detailed description:
The aim of this study is to evaluate patients converted to belatacept in combination with Mycophenolate Mofetil (MMF) with corticosteroids with respect to their DSA titer. Patients in this study will be converted from their calcineurin inhibitor (CNI) to belatacept from baseline in an attempt to down-modulate antibody production by B-cells. Dosing will be calculated per prescribing information for dosing maintenance phase (5mg per kg every 28 days.

Arms:
arm 1: Participants will be converted from their current MMF to once a month infusions of Belatacept

Interventions: intervention 1: Belatacept
Intervention descriptions: intervention 1: Patients will be converted from their MMF to Belatacept

Protocol document: